Takeda Pharmaceutical Co Ltd - Q3 FY2023 Summary
Business Context and Reporting Period
This Form 6-K filing reports Takeda Pharmaceutical Company Limited's Quarterly Securities Report for the nine-month period ended December 31, 2022 (the third quarter of the 146th Business Term). The report was filed with the Kanto Local Finance Bureau on February 7, 2023. Takeda operates as a global biopharmaceutical company with core therapeutic areas in Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies (PDT) Immunology, Oncology, and Neuroscience.
Key Financial Metrics
| Metric (Nine Months Ended Dec 31, 2022) | Value (JPY Billions) | YoY Change |
|---|---|---|
| Revenue | 3,071.3 | +13.9% (+375.6B) |
| Operating Profit | 401.9 | -13.1% (-60.5B) |
| Profit Before Tax | 327.2 | -8.3% (-29.4B) |
| Net Profit | 285.9 | +18.4% (+44.4B) |
| Core Operating Profit | 954.7 | +26.0% (+196.7B) |
| Basic EPS | 184.32 JPY | +19.6% |
| Net Cash from Operating Activities | 683.5 | -8.6% |
| Cash and Cash Equivalents | 685.1 | -5.4% |
| Total Debt (Bonds & Loans) | 4,286.9 | -1.4% |
Note: Revenue growth was driven by favorable foreign exchange rates and business momentum, offset by the prior year's one-time sale of a diabetes portfolio in Japan (133.0 billion JPY). Core Revenue grew 19.8% (4.5% at constant exchange rates).
Material Changes vs. Prior Period
- Revenue Composition: Core therapeutic areas grew 23.6% to 2,735.6 billion JPY. "Other" revenue declined 30.4% primarily due to the absence of the 133.0 billion JPY diabetes portfolio sale recorded in the prior year.
- Product Performance:
- GI: ENTYVIO sales surged 38.6% to 547.9 billion JPY, driven by US growth.
- Rare Diseases: TAKHZYRO sales increased 49.0% to 116.9 billion JPY.
- PDT Immunology: Immunoglobulin sales grew 40.3% due to strong global demand.
- Oncology: Revenue declined 3.9% due to rapid generic erosion of VELCADE (down 70.7%), partially offset by growth in ADCETRIS and ICLUSIG.
- Neuroscience: VYVANSE/ELVANSE sales increased 36.9% to 335.4 billion JPY.
- Profitability: While reported Operating Profit decreased 13.1% due to higher R&D, SG&A, and amortization expenses (impacted by yen depreciation), Core Operating Profit increased 26.0%.
- Tax Impact: Income tax expenses dropped 64.1% to 41.3 billion JPY, largely due to a one-time 64.6 billion JPY tax charge in the prior year related to the Shire acquisition break fee.
Outlook, Risks, and Unusual Items
- Management Commentary: Management highlights strong momentum in Growth and Launch products (1,199.6 billion JPY, +41.3% YoY). The company continues to focus on R&D in Innovative Biopharma, PDT, and Vaccines.
- Geopolitical Risks: Takeda has discontinued non-essential activities in Russia, including new investments and clinical trials, while maintaining supply to patients. Revenue from Russia/CIS represented 2.2% of total revenue. No material financial impact was recorded in the current period, though future results could be adversely affected.
- COVID-19: Takeda continues to manufacture and distribute NUVAXOVID in Japan and supports the distribution of SPIKEVAX (Moderna) during a transitional period.
- Unusual Items: The prior year's results included a 133.0 billion JPY revenue item from the sale of the diabetes portfolio in Japan, which is not present in the current period. Additionally, the prior year included a significant tax charge related to the Shire break fee.
Key Facts for Investor Verification
- Debt Reduction: Verify the impact of recent bond redemptions (1.219 billion USD and 750 million EUR redeemed in 2022) on future interest expenses and liquidity.
- Generic Erosion: Monitor the trajectory of VELCADE sales in the US, which dropped 70.7% due to generic competition, and assess the offsetting growth from newer oncology assets like ADCETRIS and EXKIVITY.
- Acquisition Pipeline: Confirm the closing of the Nimbus Therapeutics acquisition (NDI-034858/TAK-279), involving a 4 billion USD upfront payment, and its impact on R&D expenses and future revenue.
- Exchange Rate Sensitivity: Note that reported revenue growth (13.9%) significantly outpaced constant exchange rate (CER) growth (-0.7%), indicating heavy reliance on the weak yen for top-line performance.
- Regulatory Approvals: Track the status of LIVTENCITY (maribavir) following the AURORA trial results (did not meet primary non-inferiority endpoint) and the potential label expansion for TAKHZYRO in pediatric patients.